JP2025003912A5 - - Google Patents
Info
- Publication number
- JP2025003912A5 JP2025003912A5 JP2024115829A JP2024115829A JP2025003912A5 JP 2025003912 A5 JP2025003912 A5 JP 2025003912A5 JP 2024115829 A JP2024115829 A JP 2024115829A JP 2024115829 A JP2024115829 A JP 2024115829A JP 2025003912 A5 JP2025003912 A5 JP 2025003912A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- car
- nanobody
- active agent
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862621811P | 2018-01-25 | 2018-01-25 | |
| US62/621,811 | 2018-01-25 | ||
| PCT/US2019/015290 WO2019148037A1 (en) | 2018-01-25 | 2019-01-25 | Nanobody based imaging and targeting of ecm in disease and development |
| JP2020540721A JP7644441B2 (ja) | 2018-01-25 | 2019-01-25 | 疾患におけるecmのナノボディに基づく画像化および標的化ならびに開発 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020540721A Division JP7644441B2 (ja) | 2018-01-25 | 2019-01-25 | 疾患におけるecmのナノボディに基づく画像化および標的化ならびに開発 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025003912A JP2025003912A (ja) | 2025-01-10 |
| JP2025003912A5 true JP2025003912A5 (cg-RX-API-DMAC7.html) | 2025-10-15 |
Family
ID=67299765
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020540721A Active JP7644441B2 (ja) | 2018-01-25 | 2019-01-25 | 疾患におけるecmのナノボディに基づく画像化および標的化ならびに開発 |
| JP2024115829A Pending JP2025003912A (ja) | 2018-01-25 | 2024-07-19 | 疾患におけるecmのナノボディに基づく画像化および標的化ならびに開発 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020540721A Active JP7644441B2 (ja) | 2018-01-25 | 2019-01-25 | 疾患におけるecmのナノボディに基づく画像化および標的化ならびに開発 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US11597769B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3743443A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7644441B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112218890A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019148037A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112218890A (zh) | 2018-01-25 | 2021-01-12 | 麻省理工学院 | 在疾病和发展中基于纳米抗体的ecm成像和靶向 |
| EP4047016A1 (en) | 2021-02-19 | 2022-08-24 | Université de Strasbourg | Anti-tenascin-c (tnc) single-domain antibodies (nanobodies) and use thereof |
| CN113151177B (zh) * | 2021-05-21 | 2023-11-03 | 四川大学华西医院 | 乳腺或乳腺癌组织脱细胞基质及其制备方法和用途 |
| US20240238451A1 (en) * | 2021-05-28 | 2024-07-18 | Albert Einstein College Of Medicine | Single-domain antigen-dependent antibody-like fusion proteins |
| WO2023179370A1 (en) * | 2022-03-21 | 2023-09-28 | The Hong Kong Polytechnic University | Peptidic bispecific antibody, methods for preparation and uses thereof |
| CN117624360A (zh) * | 2022-08-26 | 2024-03-01 | 南京融捷康生物科技有限公司 | 一种抗trem2的单域抗体及其用途 |
| AU2023387779A1 (en) * | 2022-12-30 | 2024-08-22 | Remegen Co., Ltd. | Bispecific antibody and application thereof |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025175132A1 (en) * | 2024-02-15 | 2025-08-21 | Board Of Regents, The University Of Texas System | Methods for selecting triple-negative breast cancer patients for targeted therapy using tumor-specific total mrna expression |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000076456A2 (en) * | 1999-06-14 | 2000-12-21 | The General Hospital Corporation | Modulators of fibrosis |
| US9320792B2 (en) * | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
| AU2009245724A1 (en) * | 2008-05-09 | 2009-11-12 | Ablynx N.V. | Amino acid sequences directed against integrins and uses thereof |
| ES2769574T3 (es) * | 2013-03-15 | 2020-06-26 | Michael C Milone | Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva |
| EP3455245A2 (en) * | 2016-05-13 | 2019-03-20 | Orionis Biosciences NV | Therapeutic targeting of non-cellular structures |
| WO2018014039A1 (en) * | 2016-07-15 | 2018-01-18 | Poseida Therapeutics, Inc. | Chimeric antigen receptors (cars) specific for muc1 and methods for their use |
| CN112218890A (zh) | 2018-01-25 | 2021-01-12 | 麻省理工学院 | 在疾病和发展中基于纳米抗体的ecm成像和靶向 |
-
2019
- 2019-01-25 CN CN201980019075.5A patent/CN112218890A/zh active Pending
- 2019-01-25 US US16/258,457 patent/US11597769B2/en active Active
- 2019-01-25 WO PCT/US2019/015290 patent/WO2019148037A1/en not_active Ceased
- 2019-01-25 JP JP2020540721A patent/JP7644441B2/ja active Active
- 2019-01-25 EP EP19743635.5A patent/EP3743443A4/en active Pending
-
2023
- 2023-02-28 US US18/175,786 patent/US12454576B2/en active Active
-
2024
- 2024-07-19 JP JP2024115829A patent/JP2025003912A/ja active Pending
-
2025
- 2025-09-30 US US19/346,100 patent/US20260028406A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6906653B2 (ja) | 三重特異性結合タンパク質と使用方法 | |
| CN104853775B (zh) | 针对生长和分化因子15(gdf-15)的单克隆抗体 | |
| KR101820029B1 (ko) | 암의 예방 및/또는 치료에서 사용하기 위한 방사성 표지 항체 단편 | |
| JP2021119138A (ja) | 成長分化因子15(gdf−15)に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用 | |
| JP2019524745A (ja) | Fc結合能力を有する融合タンパク質を含む細胞外小胞 | |
| CA2799608C (en) | Amino acid sequences which enhance peptide conjugate solubility | |
| TW200825106A (en) | Tumor therapy with an anti-VEGF antibody | |
| CN110117329B (zh) | 包含趋化因子与结合伴侣的融合多肽及其用途 | |
| US11643437B2 (en) | Tandem repeat cancer-targeting peptides for molecular conjugation or engineering and uses thereof in cancer theranostics | |
| JP2024056787A (ja) | 抗葉酸受容体1抗体及びその使用 | |
| JP2014515600A5 (cg-RX-API-DMAC7.html) | ||
| CN118302445A (zh) | 抗cd155抗体和抗原结合片段及其使用方法 | |
| RS58918B1 (sr) | Agensi za tretman trostruko negativnog raka dojke | |
| WO2022027828A1 (zh) | 用于多特异性抗体递送的纳米适配子及其应用、构建方法 | |
| Gunaratne et al. | The characterization of variable new antigen receptors targeting FAP isolated from a novel immunized library | |
| US11458208B2 (en) | Desmoglein 2 antibody fusion proteins for drug delivery | |
| CN114269779B (zh) | 抗bag2抗体和治疗癌症的方法 | |
| CN117510642A (zh) | 一种全基因编码的双靶向嵌合体及其应用 | |
| CN114502781B (zh) | 个人化癌症免疫治疗 | |
| Gunaratne et al. | Development of FAP-targeted theranostics discovered by next-generation sequencing-augmented mining of a novel immunized VNAR library | |
| WO2022242892A1 (en) | Anti-cd38 single-domain antibodies in disease monitoring and treatment | |
| CN120058937B (zh) | 一种靶向lgr4的纳米抗体nb21及其在抗肥胖治疗中的应用 | |
| US20140302050A1 (en) | Targeting an amphiregulin-derived cell surface neo-epitope | |
| HK40090440A (en) | Anti-folate receptor 1 antibodies and uses thereof | |
| HK40122548A (en) | Anti-cd44v6 antibodies and their use to treat cd44v6 overexpressing cancers |